CN105876585A - Protein solid beverage and preparation method and application thereof - Google Patents
Protein solid beverage and preparation method and application thereof Download PDFInfo
- Publication number
- CN105876585A CN105876585A CN201610283725.5A CN201610283725A CN105876585A CN 105876585 A CN105876585 A CN 105876585A CN 201610283725 A CN201610283725 A CN 201610283725A CN 105876585 A CN105876585 A CN 105876585A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- cobastab
- parts
- solid beverage
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 77
- 239000007787 solid Substances 0.000 title claims abstract description 55
- 235000013361 beverage Nutrition 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000008280 blood Substances 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011701 zinc Substances 0.000 claims abstract description 17
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 17
- 235000016804 zinc Nutrition 0.000 claims abstract description 17
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011575 calcium Substances 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- 235000001465 calcium Nutrition 0.000 claims abstract description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011777 magnesium Substances 0.000 claims abstract description 15
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 15
- 235000001055 magnesium Nutrition 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 12
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 12
- 239000011648 beta-carotene Substances 0.000 claims abstract description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 12
- 229960002747 betacarotene Drugs 0.000 claims abstract description 12
- 239000011651 chromium Substances 0.000 claims abstract description 12
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 12
- 235000012721 chromium Nutrition 0.000 claims abstract description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000304 folic acid Drugs 0.000 claims abstract description 9
- 235000019152 folic acid Nutrition 0.000 claims abstract description 9
- 239000011724 folic acid Substances 0.000 claims abstract description 9
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 9
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 9
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 8
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 2
- 239000011715 vitamin B12 Substances 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 52
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 28
- 229940091250 magnesium supplement Drugs 0.000 claims description 14
- 229940026510 theanine Drugs 0.000 claims description 14
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 13
- 229920001202 Inulin Polymers 0.000 claims description 12
- 229940029339 inulin Drugs 0.000 claims description 12
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 11
- 229920002498 Beta-glucan Polymers 0.000 claims description 11
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 11
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 11
- 229920002752 Konjac Polymers 0.000 claims description 10
- 241000219095 Vitis Species 0.000 claims description 10
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 10
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 10
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 10
- 230000036772 blood pressure Effects 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- -1 l-cn Chemical compound 0.000 claims description 5
- 239000002075 main ingredient Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 101710089165 Protein white Proteins 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- 244000205754 Colocasia esculenta Species 0.000 claims 1
- 235000006481 Colocasia esculenta Nutrition 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 235000015096 spirit Nutrition 0.000 claims 1
- 239000011787 zinc oxide Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 16
- 201000001421 hyperglycemia Diseases 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 9
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000000630 rising effect Effects 0.000 abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 62
- 235000019197 fats Nutrition 0.000 description 40
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 206010033307 Overweight Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000032928 Dyslipidaemia Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 150000003254 radicals Chemical group 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000002485 combustion reaction Methods 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a protein solid beverage. The protein solid beverage mainly comprises protein powder, beta-glucose, L-carnitine, beta-carotene, vitamin D3, vitamin E, vitamin B1, vitamin B2, niacin, pantothenic acid, vitamin B6, folic acid, vitamin B12, vitamin C, calcium, magnesium, zinc and chromium. The protein solid beverage has the advantages that the prescription is reasonable; the problems of obesity, hyperglycemia, hyperlipidemia and hypertension are solved in the aspects of the blood glucose rising speed, blood glucose burning utilization efficiency, and fat metabolism efficiency.
Description
Technical field
The present invention relates to solid beverage field, particularly to a kind of protein solid beverage, its preparation side
Method and application.
Background technology
In recent years, along with economic development, the living standard of people is become better and better, and life stress is increasingly
Greatly, overnutrition, bad life habits or other reason causes fat and hyperglycaemia, high fat of blood and
The incidence of disease of hypertension (being commonly called as three high) rises year by year.
Obesity not only affects pretty figure, also can make troubles to life, it is often more important that easily draw simultaneously
Play multiple complications, accelerate old and feeble and dead.According to statistics, overweight people's complicated with brain embolism and heart failure is general
Rate is higher 1 times than normal type, suffers from many 2 times of the likelihood ratio regular severe one of coronary heart disease, suffers from the general of hypertension
More than regular severe one 2~6 times of rate, the probability calibration ordinary person suffering from diabetes is the highest 4 times, and cholelithiasis person is relatively
Normal person is high 4~6 times.More seriously the life-span of overweight people will substantially shorten.It has been reported that it is overweight
45 years old male sex of 10%, its life-span to shorten 4 years than regular severe one, shows according to Japan's statistics
Standard death rate is 100%, and overweight people's death rate is 127.9%.
Hyperglycaemia, high fat of blood and hypertension (being commonly called as three high), the rich man's disease derived from for modern society,
Being the mankind's fatal " number one killer ", be the common disease of more than 50 years old the elderly's health, the whole world is every
Year dies from the number of the cardiovascular and cerebrovascular disease that hyperglycaemia, high fat of blood and hypertension cause and is up to 15,000,000 people,
Occupy the various cause of the death the first.The possible individualism of hyperglycaemia, high fat of blood and hypertension, it is also possible to mutually close
Connection.Such as, diabetes may cause hyperglycaemia or high fat of blood, and high fat of blood is Atherosclerosis
That changes lures originator, and atherosclerotic may cause again hypertension, hyperglycaemia, high fat of blood and height simultaneously
Blood pressure connects each other and can aggravate the state of an illness of patient, increases the death rate.
How to be slowed down by dietotherapy and treat fat with hyperglycaemia, high fat of blood and hypertension (being commonly called as three high)
Become current people's concern.
Summary of the invention
It is an object of the invention to provide a kind of protein solid beverage, to solve in the problems referred to above
Individual or multiple.
Another object of the present invention also resides in the preparation method providing above-mentioned protein solid beverage.
Another object of the present invention also resides in the application providing above-mentioned protein solid beverage.
According to an aspect of the invention, it is provided a kind of protein solid beverage, its main component master
Material including following weight portion: the protein powder of 50~70 parts, 2.5 × 10-1~the β-Portugal of 1 part is poly-
Sugar, 5 × 10-1~the l-cn of 1 part, 1.7 × 10-3~3.5 × 10-3Part beta carotene, 2 × 10-6~
5×10-5The vitamin D of part3、1.8×10-2~1 × 10-1Part vitamin E, 2.2 × 10-3~2 × 10-2Part
Cobastab1、2.2×10-3~2 × 10-2The Cobastab of part2、3.3×10-2~1 × 10-1Part nicotinic acid,
8×10-3~1 × 10-1Part pantothenic acid, 2.2 × 10-3~1 × 10-2The Cobastab of part6、4×10-4~1 × 10-3
Part folic acid, 6.6 × 10-6~4.5 × 10-4The Cobastab of part12、2.25×10-1~5 × 10-1The dimension of part is raw
Element C, 2 × 10-1~5 × 10-1Part calcium, 1 × 10-1~3 × 10-1Part magnesium, 5 × 10-3~1 × 10-2Part
Zinc and 4.5 × 10-5~1 × 10-4The chromium of part.
In some specific embodiments, the main component of protein solid beverage can also be wrapped
Include one or more of following weight portion material: the stachyose of 3~10 parts, 8~10 parts
Inulin, the ferment powder of 5 parts, the konjaku powder of 3~5 parts, 2.5 × 10-1~5 × 10-1The theanine of part
With 1.5 × 10-1~3 × 10-1The grape pip of part.
Preferably, its Main Ingredients and Appearance of protein solid beverage of the present invention can be by following weight portion material
Composition: 66 parts of soybean separation protein white powder, 10 parts of stachyoses, 10 parts of inulin, 5 parts of konjaku powders, 5 parts
Ferment powder, 1 part of beta glucan, 5 × 10-1Part theanine, 3 × 10-1Part grape pip, 1 part of l-cn,
1.7×10-3Part beta carotene, 2.2 × 10-6Part vitamin D3、1.8×10-2Part vitamin E, 2.2 × 10-3Part
Cobastab1、2.2×10-3Part Cobastab2、3.3×10-2Part nicotinic acid, 8 × 10-3Part pantothenic acid, 2.2 × 10-3
Part Cobastab6、6×10-4Part folic acid, 6.6 × 10-6Part Cobastab12、2.25×10-1Part vitamin C,
2×10-1Part calcium, 5 × 10-3Part zinc, 1 × 10-1Part magnesium and 4.5 × 10-5Part chromium.
Preferably, its Main Ingredients and Appearance of protein solid beverage of the present invention can also be by following weight portion thing
Matter forms: 66 parts of PURE WHEYs, 10 parts of stachyoses, 10 parts of inulin, 5 parts of konjaku powders, 5 parts of ferment
Element powder, 1 part of beta glucan, 5 × 10-1Part theanine, 3 × 10-1Part grape pip, 1 part of l-cn, 1.7 × 10-3
Part beta carotene, 2.2 × 10-6Part vitamin D3、1.8×10-2Part vitamin E, 2.2 × 10-3Part dimension is raw
Element B1、2.2×10-3Part Cobastab2、3.3×10-2Part nicotinic acid, 8 × 10-3Part pantothenic acid, 2.2 × 10-3Part dimension
Raw element B6、6×10-4Part folic acid, 6.6 × 10-6Part Cobastab12、2.25×10-1Part vitamin C, 2 × 10-1
Part calcium, 5 × 10-3Part zinc, 1 × 10-1Part magnesium and 4.5 × 10-5Part chromium.
Above-mentioned calcium is can be the calcium carbonate by past protein solid beverage interpolation, calcium citrate etc.
Obtaining, magnesium then can obtain by adding magnesia, magnesium citrate etc., and zinc can be by adding oxygen
Change zinc, zinc gluconate etc. to obtain.
In some specific embodiments, the protein powder in protein solid beverage is soybean separation
Albumen powder or PURE WHEY.
In the protein solid beverage of the present invention:
The ultimate constituent of the protein in protein powder is amino acid, and amino acid is not only new thin
The necessary component of born of the same parents, is the most also to synthesize the component of enzyme necessary to new cell, therefore,
Supplementary protein powder can promote the metabolism of human body, eliminates a collection of senile cell and synthesizes new cell.
It addition, amino acid or human body carry out the key component of immunoreactive immunocyte.At proteinaceous solid
Body beverage adds protein powder, the amino acid needed for human body can be made to take in.It addition, soybean separation protein
White and lactalbumin is complete protein, and (that is: essential amino acid kind and content is complete and be provided that
The protein that human body needs) content of protein is up to 90% in soybean protein isolate, amino acid contained
Nearly 20 kinds of kind, and containing essential amino acid, containing several amino acids in lactalbumin, and
Containing essential amino acid.In protein solid beverage, add protein powder, especially add big
Beans separation albumen or lactalbumin can help human body to carry out various physiological activity.
Stachyose can promote the growth of the profitable strains such as intestinal bifidobacteria, and suppresses spoilage organisms
Increment, the profitable strain in enteron aisle can synthesize B family vitamin and a large amount of active material, it is also possible to promotees
Enter the absorption of the beneficial mineral matter such as calcium, magnesium.Meanwhile, because stachyose is a kind of functional oligose,
Can not be decomposed into glucose, human body can not directly absorb, so Blood Glucose will not be increased
Content.Thus, protein solid beverage adds stachyose, the stomach of adjustable eater, makes
The stomach of eater reaches optimum state, also will not increase blood sugar for human body content.
Inulin also belongs to functional oligose, it is possible to promote that gut flora increases and promotes intestines peristalsis,
Inulin forms SCFA and the useful thing of lactate isoreactivity through beneficial bacterium fermentative degradation in enteron aisle
Matter, uses with stachyose simultaneously and can relax bowel, and accelerates gut flora balance.
Konjaku powder is glucomannan, meets water imbibition, it is possible to increase to the 30~100 of original volume
Times, satiety can be strengthened after eater is edible, be suitable for people to lose weight as meal supplement.
Ferment is the another name of enzyme, and human cellular activity nearly all has the participation of enzyme.Ferment powder enters human body
After be degraded that (the essential great majority of enzyme are protein, can be degraded to amino acid, and amino acid is health
The required material of vital movement) or utilize (the every physiological activity participating in human body), human body will not be produced
Burden, and also human life activity is had regulation effect.
Beta glucan can promote the Bifidobacterium in enteron aisle and the growth of lactic acid bacteria beneficial bacterium, subtracts simultaneously
Few colibacillary quantity, in enteron aisle profitable strain can regulate host to the absorption of fat, storage and
Metabolism, so the increase of profitable strain beneficially human body is lost weight.Meanwhile, beta glucan is all right
The activity of regulation immunocyte, strengthens the immunity of human body.
Theanine is the natural component in tealeaves.Theanine can promote that mesencephalic centre discharges dopamine, many
Bar amine can make people produce happy, excited mood;Theanine can also promote that brain α-brain wave is released
Putting, α-brain wave makes human brain enliven, and inspiration is continuous.
Containing polyphenol substance in grape pip, polyphenol substance is free radical blocking agent, just can protect human body
Often cell is attacked from free radical, reduces the incidence of angiocardiopathy, it is also possible to improve skin quality.
Must material when l-cn is fat combustion.When l-cn lacks, fat can not get filling
The burning divided, is degraded to acid, and acid can damage human body.Heart is to utilize fat at most
Organ, need l-cn to carry out fat combustion as carrier, safeguard normal cardiac function.
Beta carotene has oxidation resistant effect, can eliminate the free radical in human body, makes human body thin
Born of the same parents are from the attack of free radical.Beta carotene can also be converted into vitamin A, vitamin A in vivo
It is the requisite material of epithelial cell, it is also possible to be converted into retinol, prevents yctalopia.Vitamin
A picked-up too much can cause vitamin A poisoning, and beta carotene only has just meeting when of needs in vivo
Being converted into vitamin A, the source making vitamin A is safer.
Vitamin D3Participating in immunological regulation in vivo after activation, the chronic inflammation that can lower matrix is avoided
Blood vessel endothelium injury.Meanwhile, vitamin D3The expression of gene can be had influence on, participate in withering of cancer cell
Die mechanism, normal vitamin D3Level can effectively reduce the risk of all kinds of cancer.
Vitamin E is a kind of important vasodilator, it is possible to reduce platelet aggregation, thus prevents
Atherosclerotic.
B family vitamin take part in organism metabolism carbohydrate, protein, fat three big energy matters
Process, liver detoxification can be helped, alleviate life stress, safeguard that nervous system normally works, ties up
Protect heart and vascular health.
Vitamin C is common water soluble antioxidant, and collagen is the main of human connective tissue
Composition, during collagen synthesis, needs ascorbic participation, and collagen is more
Synthesis can increase the elasticity of skin.Vitamin C, also known as ascorbic acid, can prevent septicemia.
Calcium is human essential elements, in human body, and either muscle, nerve, bone, there is calcium to tie
The protein closed, meanwhile, calcium is also the essential component that human body carries out the neurotransmitter of signal transmission.
Magnesium is the coenzyme that human body carries out the necessary thousands of enzyme of metabolism, and the enzyme lacking magnesium cannot
Effect brought into normal play, it is impossible to catalysis human body carries out normal biochemical reaction.
Zinc participates in synthesis and the regulation of human immunocyte, and sufficient zinc can maintain matrix to exempt from normally
Epidemic disease function, zinc still synthesizes reproduction cell essential condition, and supplementary zinc can strengthen immunity of organism
Ability, maintains normal physiological function.
Chromium is the indispensable element of human body, although the comparision contents in human body is few, but chromium is glucose
The necessary element of tolerance factor, GTF can be strengthened the effect of insulin, accelerate blood
In glucose enter cell, reduce blood-sugar content, thus reduce blood pressure.
Above-mentioned substance is combined by a certain percentage, it is possible to play conditioning obesity, hyperglycaemia, height
Blood fat and the effect of hypertension, the speed and the quickening health that control blood sugar rising to a certain extent are many
The burning of remaining fat, from the speed of blood sugar rising, the efficiency of blood sugar burning utilization, lipometabolic effect
Rate three aspect solves fat and three high problems.
Human body is after dining, and the glucose in blood can raise accordingly, after blood sugar raises, promotes pancreas islet
β cells secrete insulin, insulin promotes that the oxidative metabolism of glucose and glycogen generate, and suppression sugar is different
Raw, maintain the constant of blood sugar concentration.And the high-quality protein of beta Cell of islet repair needs abundance,
Vitamin and mineral matter, the operating efficiency of insulin is also closely related with trace element chromium, magnesium.At this
The formula of the protein solid beverage of invention adds multiple necessary vitamin, high-quality protein and ore deposit
Matter-element element.
Stachyose in formula, inulin, these compound sugar of beta glucan are with the use of increasing enteron aisle
In profitable strain, promote intestines peristalsis, there is the absorption promoting mineral element, logical intestines defecation, in advance
The effect of anti-constipation.And stachyose and inulin will not be degraded to glucose, so blood sugar will not be increased
Concentration, from without promote body increase insulin content, alleviate beta Cell of islet work pressure
(concentration of blood sugar rises stimulates islet β cell insulin to power, and insulin is that blood sugar decomposes or deposits
The required material of storage).Thus, in the protein solid drink formula of the present invention add stachyose, inulin,
Beta glucan, enough good proteins, vitamin and mineral matter, at inconspicuous increase blood-sugar content
On the basis of, promote the fast quick-recovery of beta Cell of islet, utilize from speed and the blood sugar burning of blood sugar burning
Efficiency nurse one's health obesity, reduce blood sugar, reduce blood fat and reducing blood pressure.
Fat needs to burn in the mitochondria of cell, and fat is individually to enter mitochondria,
Need carrier l-cn and can enter mitochondria burning smoothly, and with the addition of left-handed in filling a prescription
Carnitine, fat can enter mitochondria under the delivery of l-cn and burn.Thus, the present invention
Protein solid beverage in terms of fat combustion, solve obesity, hyperglycaemia, high fat of blood and hypertension
Problem.
Also added konjaku powder in the protein solid drink formula of the present invention, it is swollen that konjaku powder meets water
Swollen, the satiety of eater can be increased, make eater reduce the picked-up of food.Formula is also added with
The multiple material rich in Green Tea Extract, is possible to prevent the attack of radical pair human body cell, reduces the heart
The probability of happening of vascular diseases, improves the skin of human body.
Additionally, this formula is possibly together with theanine, theanine can promote that mesencephalic centre discharges dopamine, many
Bar amine makes people excited.Add theanine, popular feeling feelings can be made joyful.
According to another aspect of the present invention, additionally provide the preparation method of above-mentioned protein solid beverage,
Comprise the following steps: first weighing auxiliary material in proportion, the half taking each substance weight of auxiliary material knocks down mixer,
Mix;Weigh principal goods material the most in proportion, principal goods material is knocked down mixer, mixes;Finally
Remaining auxiliary material is put into mixer, mixes;
Principal goods material is the first principal goods material, or is the first principal goods material and the second principal goods material;
First principal goods material refers to: albumen powder;
Second principal goods material refers to: one or both in stachyose, inulin, konjaku powder and ferment powder
Above;
Auxiliary material is the first auxiliary material, or is the first auxiliary material and the second auxiliary material;
First auxiliary material refers to: beta glucan, l-cn, beta carotene, vitamin D3, dimension raw
Element E, Cobastab1, Cobastab2, nicotinic acid, pantothenic acid, Cobastab6, folic acid, Cobastab12、
Vitamin C, calcium, magnesium, zinc and chromium;
Second auxiliary material refers to: one or both in theanine and grape pip.
In some embodiments, the incorporation time in above-mentioned protein solid method for preparing beverage is permissible
It it is 20 minutes.
According to another aspect of the present invention, above-mentioned protein solid beverage is additionally provided in fat-reducing, fall
Hypoglycemia, reduce blood fat and/or the application of the aspect that reduces blood pressure: take the protein solid beverage of the present invention
16g, pours in the warm water of 30~50 DEG C that fill 100ml, stirs, add 200ml's
Warm water, stirs, and drinks.Every day 6 times, each 16g, altogether 96g;Morning, noon and afternoon with meal once,
Between meal and meal, snack is once.
Detailed description of the invention
In order to be illustrated more clearly that the present invention, below in conjunction with embodiment, the invention will be further described.
First weigh the auxiliary material of weight portion shown in table 1, the half of each auxiliary material weight put into material mixer,
Mixing.
Weigh the principal goods material of parts by weight shown in table 1 the most respectively,
Alleged principal goods material is put into material mixer, mixing.
Finally, remaining auxiliary material is put into material mixer, mixes 20 minutes, prepare embodiment 1~20
Protein solid beverage.
Table 1 (unit: weight portion)
In order to prove effect of present protein solid beverage, to above-mentioned prepared embodiment 3,7,
The following experiments that the protein solid beverage of 10 and 16 is carried out.
1. Germicidal efficacy object:
Experimental group 1:25 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The confession of complete supporting carbohydrate
Energy ratio about 20~25g, protein 35~40g, the dietary structure of fat 30~40g, eat simultaneously
Protein solid beverage embodiment 3 (each 16g, every day 6 times).
Experimental group 2:25 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The confession of complete supporting carbohydrate
Energy ratio about 20~25g, protein 35~40g, the dietary structure of fat 30~40g, eat simultaneously
Protein solid beverage embodiment 7 (each 16g, every day 6 times).
Experimental group 3:25 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The confession of complete supporting carbohydrate
Energy ratio about 20~25g, protein 35~40g, the dietary structure of fat 30~40g, eat simultaneously
Protein solid beverage embodiment 10 (each 16g, every day 6 times).
Experimental group 4:50 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The confession of complete supporting carbohydrate
Energy ratio about 20~25g, protein 35~40g, the dietary structure of fat 30~40g, eat simultaneously
Protein solid beverage embodiment 16 (each 16g, every day 6 times).
Control group 1:25 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The energy supply ratio of supporting carbohydrate
Example about 20~25g, protein 35~40g, the dietary structure of fat 30~40g, not edible protein
Solid beverage (each 16g, every day 6 times)
Control group 2:25 example 25~60 years old, simultaneously with overweight or fat (BMI > 24), hypertension
(> 140/90), hyperglycaemia (fasting blood-glucose > 7.0mmol/L), dyslipidemia (TG > 2.3mmol/L,
TC > 6.5mmol/L), it is commonly called as typical Metabolic Syndrome Patients.The energy supply ratio of supporting carbohydrate
Example about 55~65g, protein 10~15g, the full diet structure of fat 25~30g, not table egg
White matter solid beverage (each 16g, every day 6 times)
2. experimental result evaluation index:
1) fasting blood-glucose
2) blood fat 2 (TG, TC)
3) body weight
4) blood pressure
Table 2: intervene front laboratory biochemical indicator
Table 3: laboratory biochemical indicator after intervention
3. experimental period: 42 days
4. result:
Find the outcome evaluation index that experimental group 1, experimental group 2, experimental group 3, experimental group 4 are observed
Improvement is all had compared with control group.Wherein:
The target improvement feelings of experimental group 1 (reasonable diet matches with protein solid beverage embodiment 3)
Condition, average BMI drops to 24.3 ± 1 from 26.1 ± 0.8, and blood sugar drops to 7.9 ± 1.2 from 9.3 ± 1.9, height
Pressure drops to 138 ± 10 from 154 ± 12, and low pressure drops to 89 ± 8 from 97 ± 9, and triglycerides is from 4.4 ± 1.2
Dropping to 2.1 ± 0.5, T-CHOL drops to 5.4 ± 0.8 from 7.2 ± 1.3.
The target improvement feelings of experimental group 2 (reasonable diet matches with protein solid beverage embodiment 7)
Condition, average BMI drops to 24.5 ± 0.9 from 27 ± 0.9, and blood sugar drops to 6.7 ± 1.9 from 8.9 ± 1.7, height
Pressure drop to 129 ± 17 from 155 ± 11, low pressure drops to 86 ± 19 from 101 ± 10, triglycerides from
4.5 ± 1.5 drop to 1.8 ± 0.6, and T-CHOL drops to 3.4 ± 1.2 from 7.8 ± 1.4.
The target improvement feelings of experimental group 3 (reasonable diet matches with protein solid beverage embodiment 10)
Condition, average BMI drops to 24.4 ± 0.9 from 26.6 ± 0.8, and blood sugar drops to 7.6 ± 1.0 from 9.2 ± 1.2, height
Pressure drop to 133 ± 12 from 160 ± 10, low pressure drops to 90 ± 13 from 101 ± 12, triglycerides from
5.7 ± 1.1 drop to 1.5 ± 0.8, and T-CHOL drops to 4.6 ± 1.3 from 7.4 ± 1.
The target improvement feelings of experimental group 4 (reasonable diet matches with protein solid beverage embodiment 16)
Condition, average BMI drops to 26 ± 1.0 from 28 ± 1.4, and blood sugar drops to 7.8 ± 1.4 from 8.8 ± 1.6, high pressure
Dropping to 140 ± 10 from 158 ± 9, low pressure drops to 92 ± 7 from 98 ± 8, and triglycerides is from 5.5 ± 1
Reducing to 2.0 ± 0.2, T-CHOL drops to 5.0 ± 1.0 from 7.9 ± 1.5.
The target improvement situation of control group 1 (coordinate diet but do not match protein solid beverage), averagely
BMI drops to 25.8 ± 2.1 from 26.9 ± 1, and blood sugar drops to 8.0 ± 1.8 from 9.0 ± 1.2, and high pressure is from 153 ± 7
Dropping to 146 ± 14, low pressure drops to 97 ± 13 from 100 ± 13, and triglycerides drops to from 4.9 ± 1
3.9 ± 1, T-CHOL drops to 6.6 ± 1.6 from 7.7 ± 1.4.
The target improvement situation of control group 2 (mismatch reasonable diet and also do not match protein solid beverage),
Average BMI drops to 27.5 ± 0.5 from 27.7 ± 0.7, and blood sugar drops to 9.0 ± 1.4 from 8.9 ± 1.3, high pressure from
149 ± 16 drop to 144 ± 11, and low pressure drops to 97 ± 13 from 99 ± 10, and triglycerides is from 5.0 ± 1.3
Dropping to 4.5 ± 1.4, T-CHOL drops to 7.7 ± 1.6 from 7.9 ± 1.3.
From 4 experimental group and 2 control groups it can be seen that while supporting reasonable diet, and eat
Use protein solid beverage, obesity can be nursed one's health well, reduce blood sugar, blood fat and blood pressure.Wherein,
Protein solid beverage embodiment 10 effect is even more ideal.
When applying the protein solid beverage of the present invention, take 16g protein solid beverage, pour into and fill
In the warm water of 30~50 DEG C of 100ml, add 200ml warm water, after stirring in 5mins
Edible complete.Preferably, eater eats 6 every day, each 16g, altogether 96g, point 6 canteen use,
Morning, noon and afternoon dinner with meal 1 time, snack 1 time between eating and eating.
Above-described is only some embodiments of the present invention.For those of ordinary skill in the art
For, without departing from the concept of the premise of the invention, it is also possible to make some deformation and improvement,
These broadly fall into the protection domain of invention.
Claims (8)
1. a protein solid beverage, it is characterised in that its main component includes following weight portion
Material: the protein powder of 50~70 parts, 2.5 × 10-1~the beta glucan of 1 part, 5 × 10-1~1 part left-handed
Carnitine, 1.7 × 10-3~3.5 × 10-3Part beta carotene, 2 × 10-6~5 × 10-5The vitamin D of part3、
1.8×10-2~1 × 10-1Part vitamin E, 2.2 × 10-3~2 × 10-2The Cobastab of part1、2.2×10-3~
2×10-2The Cobastab of part2、3.3×10-2~1 × 10-1Part nicotinic acid, 8 × 10-3~1 × 10-1Part general
Acid, 2.2 × 10-3~1 × 10-2The Cobastab of part6、4×10-4~1 × 10-3Part folic acid, 6.6 × 10-6~
4.5×10-4The Cobastab of part12、2.25×10-1~5 × 10-1Part vitamin C, 2 × 10-1~5 × 10-1Part
Calcium, 1 × 10-1~3 × 10-1Part magnesium, 5 × 10-3~1-2The zinc and 4.5 × 10 of part-5~1 × 10-4Part
Chromium.
Protein solid beverage the most according to claim 1, it is characterised in that its Main Ingredients and Appearance is also
Including one or more in the material of following weight portion: the stachyose of 3~10 parts, 8~10 parts
Inulin, the ferment powder of 5 parts, the konjaku powder of 3~5 parts, 2.5 × 10-1~5 × 10~1The theanine of part
With 1.5 × 10-1~3 × 10-1The grape pip of part.
Protein solid beverage the most according to claim 2, it is characterised in that described protein
Powder is soybean separation protein white powder or PURE WHEY.
Protein solid beverage the most according to claim 3, it is characterised in that its Main Ingredients and Appearance by
The material composition of following weight portion: 66 parts of soybean separation protein white powder, 10 parts of stachyoses, 10 parts of inulin, 5
Part konjaku powder, 5 parts of ferment powders, 1 part of beta glucan, 5 × 10-1Part theanine, 3 × 10-1Part grape pip,
1 part of l-cn, 1.7 × 10-3Part beta carotene, 2.2 × 10-6Part vitamin D3、1.8×10-2Part dimension is raw
Element E, 2.2 × 10-3Part Cobastab1、2.2×10-3Part Cobastab2、3.3×10-2Part nicotinic acid, 8 × 10-3
Part pantothenic acid, 2.2 × 10-3Part Cobastab6、6×10-4Part folic acid, 6.6 × 10-6Part Cobastab12、
2.25×10-1Part vitamin C, 2 × 10-1Part calcium, 5 × 10-3Part zinc, 1 × 10-1Part magnesium and 4.5 × 10-5Part
Chromium.
Protein solid beverage the most according to claim 3, it is characterised in that its Main Ingredients and Appearance by
The material composition of following weight portion: 66 parts of PURE WHEYs, 10 parts of stachyoses, 10 parts of inulin, 5 parts of evil spirits
Taro fine powder, 5 parts of ferment powders, 1 part of beta glucan, 5 × 10-1Part theanine, 3 × 10-1Part grape pip, 1
Part l-cn, 1.7 × 10-3Part beta carotene, 2.2 × 10-6Part vitamin D3、1.8×10-2Part dimension is raw
Element E, 2.2 × 10-3Part Cobastab1、2.2×10-3Part Cobastab2、3.3×10-2Part nicotinic acid, 8 × 10-3
Part pantothenic acid, 2.2 × 10-3Part Cobastab6、6×10-4Part folic acid, 6.6 × 10-6Part Cobastab12、
2.25×10-1Part vitamin C, 2 × 10-1Part calcium, 5 × 10-3Part zinc, 1 × 10-1Part magnesium and 4.5 × 10-5Part
Chromium.
6. the protein solid beverage described in any one of Claims 1 to 5, described calcium is by calcium carbonate or lemon
Lemon acid calcium obtains, and described magnesium is obtained by magnesia or magnesium citrate, and described zinc is by zinc oxide or Portugal
Grape saccharic acid zinc obtains.
7. the preparation method of the protein solid beverage described in any one of Claims 1 to 5, its feature exists
In, comprise the following steps: first weighing auxiliary material in proportion, the half taking each substance weight of auxiliary material is knocked down mixed
Conjunction machine mixes;Weigh major ingredient input mixer the most in proportion to mix;Finally by remaining auxiliary
Material is knocked down mixer and is mixed;
Described principal goods material is the first principal goods material, or is the first principal goods material and the second principal goods material;
First principal goods material refers to: albumen powder;
Second principal goods material refers to: one or both in stachyose, inulin, konjaku powder and ferment powder
Above;
Described auxiliary material is the first auxiliary material, or is the first auxiliary material and the second auxiliary material;
The first described auxiliary material refers to: beta glucan, l-cn, beta carotene, vitamin D3、
Vitamin E, Cobastab1, Cobastab2, nicotinic acid, pantothenic acid, Cobastab6, folic acid, vitamin
B12, vitamin C, calcium, magnesium, zinc and chromium;
Described second auxiliary material refers to: one or both in theanine and grape pip.
8. the protein solid beverage described in any one of Claims 1 to 5 is in fat-reducing, reduction blood sugar, reduction
Blood fat and/or the application in reducing blood pressure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610283725.5A CN105876585A (en) | 2016-04-29 | 2016-04-29 | Protein solid beverage and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610283725.5A CN105876585A (en) | 2016-04-29 | 2016-04-29 | Protein solid beverage and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105876585A true CN105876585A (en) | 2016-08-24 |
Family
ID=56702009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610283725.5A Pending CN105876585A (en) | 2016-04-29 | 2016-04-29 | Protein solid beverage and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105876585A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106261439A (en) * | 2016-09-08 | 2017-01-04 | 深圳万和制药有限公司 | Protein Diets fiber meal replacement powder and preparation method |
CN106387593A (en) * | 2016-09-08 | 2017-02-15 | 深圳万和制药有限公司 | Protein dietary fiber solid beverage |
CN107136376A (en) * | 2017-05-31 | 2017-09-08 | 深圳瑞森健康科技有限公司 | A kind of soybean protein solid beverage |
CN107232458A (en) * | 2017-05-31 | 2017-10-10 | 深圳瑞森健康科技有限公司 | A kind of pea protein solid beverage |
CN107258927A (en) * | 2017-05-31 | 2017-10-20 | 深圳瑞森健康科技有限公司 | A kind of whey protein solids beverage |
CN107822148A (en) * | 2017-11-02 | 2018-03-23 | 光明乳业股份有限公司 | A kind of full nutritional meal replacement powder and preparation method thereof |
CN108771084A (en) * | 2018-05-28 | 2018-11-09 | 郑州清华园生物工程有限公司 | A kind of lactalbumin zinc solid beverage and preparation method thereof |
CN109077326A (en) * | 2018-05-10 | 2018-12-25 | 内蒙古天奇生物科技有限公司 | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing |
CN110313568A (en) * | 2018-12-24 | 2019-10-11 | 中健(广州)生物医药研究院有限公司 | A kind of folic acid enhancing probiotic type solid beverage and preparation method thereof |
CN113854462A (en) * | 2021-10-22 | 2021-12-31 | 上海舒泽生物科技研究所 | Solid beverage containing human body aging BAZ2B gene inhibitor and preparation method thereof |
CN115299592A (en) * | 2022-06-30 | 2022-11-08 | 杭州衡美食品科技有限公司 | Low-carbon water composition, energy rod and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187624A (en) * | 2014-08-07 | 2014-12-10 | 逯明福 | Comprehensive nutrition powder and preparation method thereof |
-
2016
- 2016-04-29 CN CN201610283725.5A patent/CN105876585A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187624A (en) * | 2014-08-07 | 2014-12-10 | 逯明福 | Comprehensive nutrition powder and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
丁晓雯等: "《保健食品原理》", 31 January 2008, 西南师范大学出版社 * |
于新等: "《谷物加工技术》", 30 April 2011, 中国纺织出版社 * |
刘富堃等: "《微生物酵素及其应用》", 31 January 2014, 辽宁科学技术出版社 * |
梁月荣: "《现代茶业全书》", 30 September 2011, 中国农业出版社 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106261439A (en) * | 2016-09-08 | 2017-01-04 | 深圳万和制药有限公司 | Protein Diets fiber meal replacement powder and preparation method |
CN106387593A (en) * | 2016-09-08 | 2017-02-15 | 深圳万和制药有限公司 | Protein dietary fiber solid beverage |
CN107136376A (en) * | 2017-05-31 | 2017-09-08 | 深圳瑞森健康科技有限公司 | A kind of soybean protein solid beverage |
CN107232458A (en) * | 2017-05-31 | 2017-10-10 | 深圳瑞森健康科技有限公司 | A kind of pea protein solid beverage |
CN107258927A (en) * | 2017-05-31 | 2017-10-20 | 深圳瑞森健康科技有限公司 | A kind of whey protein solids beverage |
CN107822148A (en) * | 2017-11-02 | 2018-03-23 | 光明乳业股份有限公司 | A kind of full nutritional meal replacement powder and preparation method thereof |
CN109077326A (en) * | 2018-05-10 | 2018-12-25 | 内蒙古天奇生物科技有限公司 | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing |
CN108771084A (en) * | 2018-05-28 | 2018-11-09 | 郑州清华园生物工程有限公司 | A kind of lactalbumin zinc solid beverage and preparation method thereof |
CN110313568A (en) * | 2018-12-24 | 2019-10-11 | 中健(广州)生物医药研究院有限公司 | A kind of folic acid enhancing probiotic type solid beverage and preparation method thereof |
CN113854462A (en) * | 2021-10-22 | 2021-12-31 | 上海舒泽生物科技研究所 | Solid beverage containing human body aging BAZ2B gene inhibitor and preparation method thereof |
CN115299592A (en) * | 2022-06-30 | 2022-11-08 | 杭州衡美食品科技有限公司 | Low-carbon water composition, energy rod and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105876585A (en) | Protein solid beverage and preparation method and application thereof | |
CN102113648A (en) | Special dietary noodle applicable to people suffering from 'five-high' metabolic syndrome and preparation method thereof | |
CN104286849A (en) | Diabetes-specific enteral nutrition multi-polymerization agent | |
AU3665701A (en) | Carbohydrate system and a method for providing nutriton to diabetic | |
CN101766635B (en) | Composite for disintoxicating and sobering | |
CN101288466A (en) | Sandwiched mushroom biscuit and preparation method thereof | |
CN101683477A (en) | Composition for fat-reducing | |
CN104430895A (en) | Total-nutritional formula milk powder and preparation method thereof | |
CN102511861A (en) | Thickened red jujube pulp added with oligosaccharide | |
CN102511864B (en) | Jujube high-consistency stock | |
KR20210051478A (en) | Easy-to-eat of Nutrition Balance Health Food | |
CN107279296A (en) | A kind of formula food of suitable diabetes and preparation method thereof | |
CN101766715B (en) | Composite for disintoxicating and sobering | |
CN102113652A (en) | Special dietary extruded rice applicable to patients suffering from 'five-high' metabolic syndrome and preparation method thereof | |
CN101766672B (en) | Composition for anti-alcohol and sobering | |
CN107455471A (en) | A kind of Sugarless type composite protein beverage and preparation method thereof | |
KR20070113460A (en) | The health food composition for regulating weight | |
CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
CN102187902A (en) | Vitamin c protein beverage, and preparation method thereof | |
CN101766637B (en) | Composite for disintoxicating and sobering | |
CN105410930A (en) | Health-care product with weight-losing and body-slimming and nutrition-balancing functions and preparation method thereof | |
CN102613461B (en) | Rapidly beautifying and weight losing nourishment and preparation method thereof | |
CN104757689A (en) | Solid beverage with pine pollen, taurine and vitamins, and preparation method of the solid beverage | |
CN105559094B (en) | A kind of high fine soybean protein freezes and preparation method thereof | |
CN101766636B (en) | Composite for disintoxicating and sobering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160824 |
|
RJ01 | Rejection of invention patent application after publication |